Top

Published in:

01-12-2021 | Prostate Cancer | Short Communication

Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset

Authors: Giovanni Adami, Davide Gatti, Maurizio Rossini, Alessandro Giollo, Eugenia Bertoldo, Ombretta Viapiana, Pietro Olivi, Angelo Fassio

Published in: Archives of Osteoporosis | Issue 1/2021

Abstract

Summary

In the present observational cohort study in 4902 men and 9804 women, we found that the factors associated with osteoporosis care utilization in men were comorbidities, adjuvant hormonal therapy for prostate cancer, vertebral or hip fractures, and glucocorticoid treatment.

Introduction

Male osteoporosis is associated with an important clinical and economic burden worldwide; nevertheless, undertreatment of men with osteoporosis is common. Understanding the factors associated with referral to bone specialists may help to define future interventions to improve access to osteoporosis care for male patients.

Methods

We conducted a retrospective analysis of a nationwide cohort (DeFRACalc79 database). DeFRACalc79 is a tool that estimates the fracture risk by considering clinical and densitometric risk factors, including the presence of prior hip or vertebral and non-vertebral or non-hip fractures. We compared the clinical characteristics of male individuals with an age-matched cohort of women. Propensity score generation with a 2:1 female-to-male ratio was performed using a logistic regression model to age-match the cohorts.

Results

We analyzed a sample of 4902 men at high risk for osteoporosis. We found that the factors associated with osteoporosis care utilization in men were the presence of comorbidities (OR 1.939, 95% CI 1.799–2.090), adjuvant hormonal therapy for prostate cancer (OR 1.482, 95% CI 1.315–1.670), the presence of vertebral or hip fractures (OR 1.490, 95% CI 1.378–1.611), and glucocorticoid treatment (OR 2.573, 95% CI 2.274–2.832).

Conclusions

Men are more commonly referred to the bone specialist with a prevalent fragility fracture and/or diagnosis of secondary osteoporosis as compared with women. Our study suggests that there is a lack of screening for the primary prevention of osteoporosis in men as compared with that in women.

Adler RA (2014) Osteoporosis in men: a review. Bone Res 2:1–8. https://doi.org/10.1038/boneres.2014.1CrossRef

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465–475. https://doi.org/10.1359/jbmr.061113CrossRefPubMed

Nguyen ND, Ahlborg HG, Center JR et al (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788. https://doi.org/10.1359/jbmr.070315CrossRefPubMed

Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M (2017) Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet 389:1323–1335. https://doi.org/10.1016/S0140-6736(16)32381-9CrossRefPubMedPubMedCentral

van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517–522. https://doi.org/10.1016/s8756-3282(01)00614-7CrossRefPubMed

Hopkins RB, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Leslie WD, Tarride JE, Thabane L (2012) Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 23:921–927. https://doi.org/10.1007/s00198-011-1652-8CrossRefPubMed

Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217–2222. https://doi.org/10.1001/archinte.162.19.2217CrossRefPubMed

Adami G, Rossini M, Fassio A et al (2020) Comments on Kanis et al.: Algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. Osteoporos Int. https://doi.org/10.1007/s00198-020-05302-6

Adami G, Giollo A, Rossini M, Orsolini G, Benini C, Viapiana O, Gatti D, Fassio A (2020) Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo 72:71–74. https://doi.org/10.4081/reumatismo.2020.1267CrossRefPubMed

10.

Adami G, Gatti D, Rossini M, Orsolini G, Pollastri F, Bertoldo E, Viapiana O, Bertoldo F, Giollo A, Fassio A (2020) Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporos Int 31:2113–2122. https://doi.org/10.1007/s00198-020-05519-5CrossRefPubMed

11.

Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156. https://doi.org/10.1007/s00198-019-04906-xCrossRefPubMed

12.

Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388–393. https://doi.org/10.1097/BOR.0000000000000608CrossRefPubMed

13.

Merrill RM, Weed DL, Feuer EJ (1997) The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomark Prev 6:763–768

14.

Narla RR, Hirano LA, Lo SHY, Anawalt BD, Phelan EA, Matsumoto AM (2019) Suboptimal osteoporosis evaluation and treatment in older men with and without additional high-risk factors for fractures. J Investig Med 67:743–749. https://doi.org/10.1136/jim-2018-000907CrossRefPubMed

15.

Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawka AM, Goltzman D, Tenenhouse A, Pickard L, Olszynski WP, Davison KS, Kaiser S, Josse RG, Kreiger N, Hanley DA, Prior JC, Brown JP, Anastassiades T, Adachi JD, CaMos Research Group (2008) The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 19:581–587. https://doi.org/10.1007/s00198-007-0483-0CrossRefPubMed

16.

European Prospective Osteoporosis Study (EPOS) Group, Felsenberg D, Silman AJ et al (2002) Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724. https://doi.org/10.1359/jbmr.2002.17.4.716CrossRef

Title: Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset
Authors: Giovanni Adami
Davide Gatti
Maurizio Rossini
Alessandro Giollo
Eugenia Bertoldo
Ombretta Viapiana
Pietro Olivi
Angelo Fassio
Publication date: 01-12-2021
Publisher: Springer London
Keywords: Prostate Cancer
Glucocorticoid
Prostate Cancer
Care
Osteoporosis
Osteoporosis
Published in: Archives of Osteoporosis / Issue 1/2021
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-021-00915-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Disease progression associated with low bone mass in axial spondyloarthropathy patients

Maternal vitamin D and offspring fracture risk: the Vitamin D in Pregnancy study

Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland

Incidence of fractures among patients receiving medications for type 2 diabetes or chronic obstructive pulmonary disease and glucocorticoid users according to the National Claims Database in Japan

Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey

Associations between bone mineral density in different measurement locations and coronary artery disease: a cross-sectional study